Cargando…

Predicting Microenvironment in CXCR4- and FAP-Positive Solid Tumors—A Pan-Cancer Machine Learning Workflow for Theranostic Target Structures

SIMPLE SUMMARY: Imaging based on positron emission tomography (PET) is a crucial part of up-to-date cancer care. For this purpose, PET employs and marks target structures at the cellular surface. Recently, C-X-C Motif Chemokine Receptor 4 (CXCR4) and Fibroblast Activation Protein Alpha (FAP) emerged...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marquardt, André, Hartrampf, Philipp, Kollmannsberger, Philip, Solimando, Antonio G., Meierjohann, Svenja, Kübler, Hubert, Bargou, Ralf, Schilling, Bastian, Serfling, Sebastian E., Buck, Andreas, Werner, Rudolf A., Lapa, Constantin, Krebs, Markus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9856808/ https://www.ncbi.nlm.nih.gov/pubmed/36672341 http://dx.doi.org/10.3390/cancers15020392

Ejemplares similares

Subgroup-Independent Mapping of Renal Cell Carcinoma—Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries
por: Marquardt, André, et al.
Publicado: (2021)

CXCR4-directed theranostics in oncology and inflammation
por: Kircher, Malte, et al.
Publicado: (2018)

CXCR4-targeted theranostics in oncology
por: Buck, Andreas K., et al.
Publicado: (2022)

miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro
por: Krebs, Markus, et al.
Publicado: (2020)

Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT
por: Serfling, Sebastian E., et al.
Publicado: (2022)

CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas
por: Weich, Alexander, et al.
Publicado: (2021)

Targeting CXCR4 with [(68)Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?
por: Lapa, Constantin, et al.
Publicado: (2017)

Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics
por: Habringer, Stefan, et al.
Publicado: (2018)

CXCR4-targeted molecular imaging after severe SARS-Cov-2 infection
por: Lambertini, Alessandro, et al.
Publicado: (2022)

Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [(177)Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome
por: Hartrampf, Philipp E., et al.
Publicado: (2021)

Radioligands Targeting Fibroblast Activation Protein (FAP)
por: Lindner, Thomas, et al.
Publicado: (2021)

Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results?
por: Hartrampf, Philipp E., et al.
Publicado: (2020)

Theranostics in Hematooncology
por: Buck, Andreas K., et al.
Publicado: (2023)

Visual Clustering of Transcriptomic Data from Primary and Metastatic Tumors—Dependencies and Novel Pitfalls
por: Marquardt, André, et al.
Publicado: (2022)

Critical Evaluation of a microRNA-Based Risk Classifier Predicting Cancer-Specific Survival in Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava
por: Kotlyar, Mischa J., et al.
Publicado: (2023)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging
por: Kosmala, Aleksander, et al.
Publicado: (2023)

In Vivo Targeting of CXCR4—New Horizons
por: Schottelius, Margret, et al.
Publicado: (2021)

Pitfalls in PSMA-PET/CT: intensive bone marrow uptake in a case with polycythemia vera
por: Hartrampf, Philipp E., et al.
Publicado: (2020)

Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?
por: Roustaei, Hessamoddin, et al.
Publicado: (2022)

Detection Rate of (68)Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy
por: Brumberg, Joachim, et al.
Publicado: (2020)

CXCR4-Directed Imaging in Solid Tumors
por: Werner, Rudolf A., et al.
Publicado: (2019)

Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4–Directed Molecular Imaging and Therapy
por: Hartrampf, Philipp E., et al.
Publicado: (2023)

NRF2 Enables EGFR Signaling in Melanoma Cells
por: Kreß, Julia Katharina Charlotte, et al.
Publicado: (2021)

Aplastic Anemia as a Roadmap for Bone Marrow Failure: An Overview and a Clinical Workflow
por: Solimando, Antonio G., et al.
Publicado: (2022)

Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [(177)Lu]Lu-PSMA I&T during long-term follow-up
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Hypoxia-Independent Drivers of Melanoma Angiogenesis
por: Meierjohann, Svenja
Publicado: (2015)

Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy
por: Michalski, Kerstin, et al.
Publicado: (2020)

mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma
por: Serfling, Sebastian E., et al.
Publicado: (2022)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?
por: Werner, Rudolf A., et al.
Publicado: (2018)

Effect of human cytomegalovirus (HCMV) US27 on CXCR4 receptor internalization measured by fluorogen-activating protein (FAP) biosensors
por: Boeck, Jordan M., et al.
Publicado: (2017)

Change of offices for the FAP Department
por: FAP Department
Publicado: (2016)

Spheroids of FAP-Positive Cell Lines as a Model for Screening Drugs That Affect FAP Expression
por: Pleshkan, Victor V., et al.
Publicado: (2023)

Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CT
por: Mihatsch, Patrick W., et al.
Publicado: (2022)

SUV(mean) on baseline [(18)F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2023)

Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI
por: Linz, Christian, et al.
Publicado: (2021)

Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung Cancer
por: Serfling, Sebastian E., et al.
Publicado: (2023)

Pan-cancer analysis of CXCR4 carcinogenesis in human tumors
por: Wang, Sen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uoomonfmpatdf8l1hlfbup3ptb